Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes

September 7, 2011 By Bio-Medicine.Org

RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 7, 2011 /PRNewswire/
— Boehringer Ingelheim and Eli Lilly and Company (NYSE:
LLY
) will present the latest data from their diabetes portfolio
at the 47th Annual Meeting of the European Association for the
Study of Diabetes (EASD) in Lisbon, Portugal, September 12-16.
Study results evaluating the dipeptidyl peptidase-4 (DPP-4)
inhibitor, linagliptin, as well as the investigational
sodium-dependent glucose co-transporter-2 (SGLT-2) inhibitor,
empagliflozin (BI-10773), will be featured among the seven
presentations. Linagliptin 5 mg is marketed under the trade name
Tradjenta™ (linagliptin) tablets in the U.S. and was approved
by the U.S. Food and Drug Administration (FDA) in May 2011 to be
used along with diet and exercise to lower blood sugar in adults
with type 2 diabetes. TRADJENTA should not be used in patients with
type 1 diabetes or for the treatment of diabetic ketoacidosis
(increased ketones in the blood or urine). It has not been studied
in combination with insulin.

A long-term study evaluating the efficacy and safety of
linagliptin in patients with type 2 diabetes was selected by EASD
as an oral presentation, taking place on Friday, September 16.

The presentations are as follows: Linagliptin DataTitleFormat
AuthorsDate/TimePreclinicalDPP-4 Inhibition – A New Approach for
the Treatment of Uraemic Cardiomyopathy

Poster

824-P

L Chaykovska, K von Websky, S Heiden, J Rahnenfuhrer, T Klein, B
Hocher

Date: Tues, Sept. 13

Time: 12:30−1:30 p.m.Phase III (52-week)Long-term Efficacy
and Safety of Linagliptin in Patients with Type 2 Diabetes and
Severe Renal Impairment

Poster

821-P

J Newman, J McGill, S Patel, C Friedrich, C Sauce, H-J
Woerle

Date: Tues, Sept. 13

Time: 12:30−1:30 p.m.Phase III (pooled
analysis)Linagliptin Improves

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech